Injective (INJ) is currently priced at $3.10, reflecting a 2.75% increase over the past 24 hours. The daily trading range has been tight, with a high of $3.11 and a low of $3.02, indicating relatively stable price movement within this timeframe.

The trading volume stands at approximately 29.59 million, constituting 9.51% of its market cap, suggesting healthy trading activity relative to its overall value. Short-term moving averages indicate bullish momentum, with the 8, 13, and 21 SMA all showing positive growth rates of 1.05%, 1.23%, and 1.41%, respectively.

The 1-hour RSI is at 65, nearing the overbought threshold, while the 7-day RSI at 56 suggests a more balanced market sentiment. Price performance over the past week has shown a notable increase of about 9.38%, while the 14-day change is also positive at 5.05%, indicating upward momentum.

In contrast, the 30-day price change has slightly declined by 0.57%, suggesting potential consolidation or market correction phases. The all-time high of $52.62 reached in March 2024 remains significantly distant, indicating substantial room for growth if bullish conditions persist.

Given the strong short-term momentum indicated by the moving averages and RSI metrics, alongside a solid volume performance, the outlook for INJ appears positive. However, caution is warranted due to the proximity of the 1-hour RSI to the overbought level.

Based on the current analysis, a Buy rating is recommended, as the technical indicators suggest continued upward momentum in the near term, with potential for further gains. Traders should monitor the RSI levels closely to avoid entering at peak overbought conditions.